TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06708897: A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Sponsor: Lomond Therapeutics Holdings, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$9,707,544

Rescue Site Savings

+$6,408,864

Unlock Full NCT06708897 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06708897 Rescue Dossier →